100Xfounder
Get Featured

MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases. Healthcare Biotech

About MedGenome

The Problem MedGenome addresses a core healthcare pain point: fragmented operations, slow decision cycles, and poor visibility across teams. Organizations in this market often rely on disconnected tools, which creates delays, revenue leakage, and inconsistent customer outcomes.

The Solution MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases. Healthcare Biotech In practice, MedGenome centralizes critical workflows, automates repetitive coordination, and gives operators a real-time system of record. This reduces manual overhead and improves execution quality at scale.

Why it's growing With the rise of digitized healthcare workflows, preventive analytics, and patient-first digital journeys, MedGenome is positioned to capture sustained demand. Buyers now prioritize speed, reliability, and clear ROI, and the company aligns directly with those purchasing criteria.

Culture The team operates in a fast-paced environment focused on healthcare innovation, product velocity, and customer-centric execution. Their culture emphasizes ownership, experimentation, and measurable outcomes.

Why it Matters

MedGenome matters now because with the rise of digitized healthcare workflows, preventive analytics, and patient-first digital journeys, MedGenome is positioned to capture sustained demand. Buyers now prioritize speed, reliability, and clear ROI, and the company aligns directly with those purchasing criteria.

Funding Snapshot

Total Funding: $55.00MLast Round: Series C Sequoia, $55M Series C in 2020, $95M valuationAll Rounds: 1
  • Series CSequoia, $55M Series C in 2020, $95M valuation

Hiring Roles

This company is actively hiring.

Open Roles

Meet the Founders

Tech Stack

PythonGCPBigQueryReact

Last updated: February 23, 2026

MedGenome intelligence brief

This profile combines core company context with linked founder, funding, and newsroom routes so readers can evaluate business momentum without switching across multiple tools. Use it as a baseline for comparing peers in the same industry and stage.

For deeper validation, pair this page with founder profile, company news coverage, and stage-based funding hubs to contextualize updates against wider market movement.

Related Companies

Alternatives in Healthcare with comparable market signals.

Discover Now

Newsroom and topic pages connected to MedGenome.

No company-specific newsroom stories available yet.

Contextual Research Links

Jump to country, industry, stage, startup taxonomy, and newsroom routes tied to this company.

Want to get featured on 100Xfounder?

Want your company featured with founder details and funding visibility? Start here.

FAQs About MedGenome

Common questions people ask about this profile.

What is MedGenome?

MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases. Healthcare Biotech

Who founded MedGenome?

MedGenome is associated with MedGenome Team on 100Xfounder.

Where is MedGenome located?

MedGenome is listed in Bangalore, India.

What stage is MedGenome in?

MedGenome is currently mapped to Series C. Funding context: Sequoia, $55M Series C in 2020, $95M valuation

What is the latest funding round of MedGenome?

MedGenome's latest tracked round is Series C Sequoia, $55M Series C in 2020, $95M valuation. Total tracked rounds: 1.

Is MedGenome hiring now?

MedGenome hiring status: Open Roles.

What technologies does MedGenome use?

MedGenome is associated with Python, GCP, BigQuery, and React.

Is MedGenome verified on 100Xfounder?

Yes. MedGenome is currently marked verified on 100Xfounder as of March 3, 2026.

How can users connect with MedGenome founders?

Users can open founder profiles, use listed company links, and track signal updates directly from the 100Xfounder directory.